MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year,

AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of

GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new CEO Luke Miels.

A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main driving factor.

The FDA is launching a pilot program to collect and review clinical trial data in real time, giving scientific reviewers access to the data as